All In Biotech

Investigational drug · Phase 3

Non-immunogenic recombinant staphylokinase

Also called: Fortelyzin

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pulmonary Embolism.

Phase 3

Last checked: Nov 20, 2026Latest source record: Dec 5, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

5

Any phase or sponsor naming "Non-immunogenic recombinant staphylokinase"

First trial start

2024

May 23, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Non-immunogenic recombinant staphylokinase", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Pulmonary Embolism

Approved drugs for the same conditions: Blood clots (DVT and pulmonary embolism)

Largest trials

Live from ClinicalTrials.gov: studies naming "Non-immunogenic recombinant staphylokinase" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 13 on PubMed

Also in development for Pulmonary Embolism

  • TS23Phase 22 trials

    Translational Sciences, Inc. · Ischemic Stroke, Pulmonary Embolism

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.